3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Rectal Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adrenocortical Carcinoma
1
Adenocarcinoma of Lung
1
Interventions
Irinotecan
58
Bevacizumab
56
Oxaliplatin
49
Leucovorin
49
Fluorouracil
49
Capecitabine
45
Cetuximab
44
pembrolizumab
23
IFL protocol
15
Nivolumab
11
regorafenib
10
Panitumumab
10
Celecoxib
8
Radiotherapy
7
Cyclophosphamide
7
atezolizumab
6
Surgical Procedures, Operative
6
Gemcitabine
6
Folfox protocol
6
Colonoscopy
6
trifluridine tipiracil drug combination
5
Neoadjuvant Therapy
5
Metformin
5
Immunohistochemistry
5
Biopsy
5
tislelizumab
4
spartalizumab
4
durvalumab
4
Trastuzumab
4
Mitomycin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Colorectal Neoplasms
×
cixutumumab
×
Clear all
NCT00845039
2018-07-02
FC-4
Eli Lilly and Company
Phase 2
Terminated
4 enrolled
9 charts